계명대학교 의학도서관 Repository

A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis

Metadata Downloads
Author(s)
Do Seon SongMyeong Jun SongSi Hyun BaeWoo Jin ChungJae Young JangYoung Seok KimSae Hwan LeeJun Yong ParkHyung Joon YimSung Bum ChoSoo Young ParkJin Mo Yang
Keimyung Author(s)
Chung, Woo Jin
Department
Dept. of Internal Medicine (내과학)
Journal Title
Journal of Gastroenterology
Issued Date
2015
Volume
50
Issue
4
Keyword
Hepatic arterial infusion chemotherapySorafenibHepatocellular carcinomaPortal vein tumor thrombosis
Abstract
Background

The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).


Methods

A total of 110 patients were observed between February 2008 and May 2013 in seven Korean centers. Fifty patients were treated with HAIC, and 60 patients were treated with sorafenib.


Results

The disease control rate in the HAIC was significantly higher than that in the sorafenib group (p < 0.001), although there was no significant difference in the objective response rate (p = 0.214). The median overall survival (OS) was significantly longer in the HAIC group than in the sorafenib group (7.1 vs. 5.5 months, p = 0.011). The median time to-progression (TTP) was also significantly longer in the HAIC group than in the sorafenib group (3.3 vs. 2.1 months, p = 0.034). In the multivariate analysis, tumor diameter (≥ 10 cm) and the absence of combined loco-regional treatment were significant prognostic factors influencing OS (p = 0.002 and p = 0.010, respectively) and TTP (p = 0.017 and p = 0.006, respectively). The treatment modality tended to be a significant prognostic factor for survival (p = 0.052), but not for tumor progression (p = 0.121).


Conclusions

HAIC is comparable with sorafenib in terms of OS and TTP in advanced HCC patients with PVTT. HAIC shows more favorable treatment responses compared with sorafenib. Therefore, HAIC might be an alternative treatment modality to sorafenib in advanced HCC patients with PVTT.
Keimyung Author(s)(Kor)
정우진
Publisher
School of Medicine
Citation
Do Seon Song et al. (2015). A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Journal of Gastroenterology, 50(4), 445–454. doi: 10.1007/s00535-014-0978-3
Type
Article
ISSN
0944-1174
Source
https://link.springer.com/article/10.1007%2Fs00535-014-0978-3
DOI
10.1007/s00535-014-0978-3
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/33779
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.